MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing ...
AZoM

How Floquet Engineering Can Control Material Properties

Floquet control uses time-periodic drives to engineer quantum systems, creating dynamic changes in material properties ...

Imbria Pharmaceuticals Announces Publication of IMPROVE-DiCE Phase 2a Data in Circulation, Demonstrating Ninerafaxstat as a Potential First-in-Class Therapy Targeting Cardiac ...

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...
TMCnet

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Neurosterix was spun-out of Addex in April 2024, raising $65 million in a Series A financing led by funds affiliated with Perceptive Advisors. Addex retains a 20% equity interest in Neurosterix.
IEEE

A Calibration-Free Adpll with -80 dBc Fractional Spur Based on Pseudo-Random Phase Modulation

Abstract: This work presented a fractional-N digital PLL that leveraged pseudo-random phase modulation and demodulation technique to mitigate fractional spurs. By decoupling the periodicity of control ...
Morning Overview on MSN

A dust-sized device could supercharge quantum computers

A device smaller than a grain of dust is emerging as a surprisingly powerful candidate to reshape how quantum computers are ...